Four companies have announced the recall of several batches of prescription drugs in use in Canada.
Health Canada said it has not received any reports of adverse effects related to the medications, and the recall is a precautionary measure.
A statement released this morning said the decision was made after the four companies — Cobalt Pharmaceuticals, Laboratoire Riva, Mylan Pharmaceuticals and Sanis Health — consulted with Health Canada.
Drugs affected by recall are certain lots of:
- Amlodipine, used in the treatment of hypertension or high blood pressure and angina or chest pain.
- Ciprofloxacin used to treat infections such as acute bronchitis, urinary tract infections, travellers' diarrhea.
- Norfloxacin, also used to treat the infections listed above.
- Lamotrigine, used in the treatment of epilepsy.
- Telmisartan, used in the management of hypertension.
Patients taking any of the listed drugs are advised not to discontinue their treatment until first consulting with their physician.
Cobalt Pharmaceuticals noted the recall covers particular lots of its norfloxacin and telmisartan products only.
Mylan Pharmaceuticals' recalled products included particular doses and lot numbers of lamotrigine, amlodipine and ciprofloxacin.
Sanis Health's recalled products were certain doses and lot numbers of lamotrigine and amlodipine.
Laboratoire Riva's recall was for two lots of its 500-milligram ciprofloxacin.
In an email to CBC News, Health Canada said the issues are mainly related to processes that affect quality control and oversight.
"This action is not anticipated to disrupt the overall supply for these products, as alternative manufacturers supplying the Canadian market are not affected," a spokesperson for the department said.
Health Canada said it was informed by the European Directorate for Quality of Medicines & Health Care about the European agency's recent inspection of Smruthi Organics Limited of India, where the active pharmaceutical ingredients used in the manufacturing of the recalled products were sourced.
The department said more information will be publicly available after the European agency releases its final inspection reports.
For more information, people can contact Health Canada toll free at 1-866-225-0709.